Literature DB >> 12425506

Monofocal acute inflammatory Demyelination (MAID): a unique disorder simulating brain neoplasm.

José A Gutrecht1, Joseph R Berger, Royden H Jones, Andrew C Mancall.   

Abstract

BACKGROUND: Monofocal acute inflammatory demyelinating (MAID) lesions present as large masses that mimic brain tumors. The natural history and nosologic classification are not well defined.
METHODS: Five patients with MAID from our files and 4 from the literature are presented. We defined MAID as a mass-like lesion, >4 cm in diameter. Demyelination was pathologically proven in all patients.
RESULTS: Headaches and motor deficits were the most common presenting symptoms. Language problems and motor deficits were the most common findings on physical examination. After a median follow-up of 44 months, none of our 5 patients had multiple sclerosis. In similar cases, additional lesions indicative of multiple sclerosis developed within an average of 8 months.
CONCLUSIONS: It may be difficult to distinguish MAID from brain tumor. It may be that MAID represents a unique form of isolated demyelinating disease, or it may represent transition to multiple sclerosis.

Entities:  

Mesh:

Year:  2002        PMID: 12425506

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  3 in total

1.  Variant of multiple sclerosis with dementia and tumefactive demyelinating brain lesions.

Authors:  Sherifa A Hamed
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

2.  Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.

Authors:  Hussam A Yacoub; Zaid A Al-Qudahl; Huey-Jen Lee; Ada Baisre; Nizar Souayah
Journal:  J Vasc Interv Neurol       Date:  2011-07

Review 3.  Schilder's disease: non-invasive diagnosis? :A case report and review.

Authors:  Susanna Bacigaluppi; Gabriele Polonara; Mario L Zavanone; Rolando Campanella; Vincenzo Branca; Sergio M Gaini; Giovanni Tredici; Antonella Costa
Journal:  Neurol Sci       Date:  2009-07-17       Impact factor: 3.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.